ArticleBMC pulmonary medicine2025
Cost effectiveness of a novel swallowing and respiratory sensation assessment and a modelled intervention to reduce acute exacerbations of COPD.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The relationship between swallowing function and clinical parameters in patients with chronic obstructive pulmonary disease.BMC pulmonary medicine · 2026Article
- Development and Validation of an Explainable Machine Learning Model for Identification of Dysphagia in Patients with COPD.International journal of chronic obstructive pulmonary disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Swallowing impairment observed in ~ 20% of people with Chronic Obstructive Pulmonary Disease (COPD) may increase the risk of aspiration pneumonia and acute exacerbations. We designed a decision analytic model to assess the cost-effectiveness of the Swallowing and Respiratory Sensation Assessment (SwaRSA) tests and swallowing rehabilitation to reduce COPD exacerbations. We believe that swallowing rehabilitation to improve coordination of swallowing and breathing may reduce exacerbations in people with COPD.From the Australia health system perspective, we assessed the cost effectiveness of four tests relative to standard of care, or no testing, over a time horizon of one year. The SwaRSA tests assessed relative to a standard of care arm of no testing: included the Eating Assessment Tool (EAT-10) score, Swallowing Capacity of Liquids, Tongue Strength Assessment, and Respiratory Sensation Assessment, in people with moderate to severe COPD. Outcome measures were COPD exacerbations per year, which were converted into quality adjusted life years (QALYs). Model inputs including costs, test sensitivities and specificities, COPD exacerbation risks, and exacerbation-related utilities were derived from published sources. Our assumptions on the costs, recovery, and risk reduction are based on the available data on pulmonary rehabilitation in COPD.Relative to no-SwaRSA, three individual testing strategies were found to be cost-effective at incremental cost effectiveness ratio per QALY ranging from $27,000 to $37,000 AUD assuming a willingness to pay of $50,000 AUD. The EAT-10 and the tongue strength were the two dominant options on the cost-effectiveness frontier. Model results were robust to variations in one-way and probabilistic sensitivity analyses.In COPD, SwaRSA modelling suggests that self-assessment with the EAT-10 and subsequent intervention is highly cost-effective relative to no-SwaRSA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.